Recent News

• 05.26.2026 - Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
• 05.14.2026 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 05.13.2026 - Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
• 05.01.2026 - Esperion to be Acquired by ARCHIMED
• 04.23.2026 - Esperion to Report First Quarter 2026 Financial Results on May 7
• 04.02.2026 - Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
• 03.31.2026 - Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
• 03.30.2026 - Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

Recent Filings

• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.01.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.01.2026 - EX-99.1 EX-99.1
• 05.01.2026 - 8-K Current report
• 05.01.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.22.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.16.2026 - DEF 14A Other definitive proxy statements
• 04.16.2026 - ARS Annual Report to Security Holders
• 04.16.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material